Literature DB >> 16738694

Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects.

A R Pettitt, E Matutes, D Oscier.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16738694     DOI： 10.1038/sj.leu.2404265

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  10 in total

1.  Tailoring of chronic lymphatic leukemia therapy.

Authors:  Ashraf M Elhefni
Journal:  Am J Blood Res       Date:  2013-08-19

Review 2.  Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach.

Authors:  Clive S Zent; Neil E Kay
Journal:  Leuk Lymphoma       Date:  2011-06-08

3.  Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study.

Authors:  M van Gelder; M H van Oers; W G Alemayehu; M C J Abrahamse-Testroote; J J Cornelissen; M E Chamuleau; P Zachée; M Hoogendoorn; M Nijland; E J Petersen; A Beeker; G-J Timmers; L Verdonck; M Westerman; O de Weerdt; A P Kater
Journal:  Bone Marrow Transplant       Date:  2016-02-15       Impact factor: 5.483

4.  Prognostic Role of Lymphocyte/Monocyte Ratio in Chronic Lymphocytic Leukemia.

Authors:  Osman Yokus; Esma Nur Saglam; Hasan Goze; Fettah Sametoglu; Istemi Serin
Journal:  J Hematol       Date:  2020-10-01

5.  p53: a molecular marker for the detection of cancer.

Authors:  Mark T Boyd; Nikolina Vlatkovic
Journal:  Expert Opin Med Diagn       Date:  2008-09

6.  Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use.

Authors:  Jeremy L Warner; Jon E Arnason
Journal:  Ther Adv Hematol       Date:  2012-12

Review 7.  Alemtuzumab for patients with chronic lymphocytic leukaemia.

Authors:  Nicole Skoetz; Kathrin Bauer; Thomas Elter; Ina Monsef; Verena Roloff; Michael Hallek; Andreas Engert
Journal:  Cochrane Database Syst Rev       Date:  2012-02-15

8.  State-of-the-Art Management of Patients Suffering from Chronic Lymphocytic Leukemia.

Authors:  Ruth Clifford; Anna Schuh
Journal:  Clin Med Insights Oncol       Date:  2012-03-19

9.  Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL).

Authors:  Marco Montillo; Francesca Ricci; Sara Miqueleiz; Alessandra Tedeschi; Enrica Morra
Journal:  Biologics       Date:  2008-03

10.  Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia.

Authors:  Martin Šimkovič; Monika Motyčková; David Belada; Pavel Vodárek; Rahul Kapoor; Hamna Jaffar; Filip Vrbacký; Pavel Žák; Lukáš Smolej
Journal:  Arch Med Sci       Date:  2015-12-08       Impact factor: 3.318
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.